Quantitative [18F]PSMA-1007 PET in Treatment Response Monitoring of Brain Metastases from Non-small Cell Lung Cancer

PURPOSE: F]PSMA-1007 uptake and treatment response in BMs of patients with non-small cell lung cancer (NSCLC). PROCEDURES: ). Standardised uptake value (SUV), biological tumour volume (BTV) and tumour heterogeneity using the coefficient of variance (CoV) were assessed. RESULTS: in the lungs were 6.1 g/ml (range: 3.2-13.6 g/ml) at the initial exam and 6.3 g/ml (range: 3.8-11.8 g/ml) at the second exam. CONCLUSION: F]PSMA-1007 PET is a promising diagnostic tool for BMs from NSCLC. The uptake and heterogeneity, along with the marked reduction post-therapy, highlights its potential for monitoring treatment response. TRIAL REGISTRATION: Clinicaltrials.gov, NCT03951142. Registered 5 October 2019, https://clinicaltrials.gov/ct2/show/NCT03951142 . EudraCT no 2018-003229-27. Registered 26 February 2019, https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-003229-27/NO .